| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| K A Gronau, P L Brubake. Mechanism of action of glucagon-like peptide-1(7-36NH2) in isolated rat pancreatic islets and abrogation of its effects in long-term incubations. Endocrine. vol 3. issue 11. 2012-10-02. PMID:21153123. |
however, neither the effects of glp-1(7-37/36nh2) on the protein kinase a pathway nor its chronic effects on insulin secretion have been examined in normal b cells. |
2012-10-02 |
2023-08-12 |
rat |
| K A Gronau, P L Brubake. Mechanism of action of glucagon-like peptide-1(7-36NH2) in isolated rat pancreatic islets and abrogation of its effects in long-term incubations. Endocrine. vol 3. issue 11. 2012-10-02. PMID:21153123. |
glp-1(7-36nh2) (10(-8)m) increased islet camp content to 391±196% of control after 30 min of incubation (p<0.05), and stimulated glucose-dependent insulin secretion by 2.0±0.1-fold in acutely perifused islets (p<0.001). |
2012-10-02 |
2023-08-12 |
rat |
| K A Gronau, P L Brubake. Mechanism of action of glucagon-like peptide-1(7-36NH2) in isolated rat pancreatic islets and abrogation of its effects in long-term incubations. Endocrine. vol 3. issue 11. 2012-10-02. PMID:21153123. |
however, 10(-8) m glp-1(7-36nh2) did not stimulate insulin secretion at either 5 or 10 mm glucose, or in the presence of forskolin and ibmx. |
2012-10-02 |
2023-08-12 |
rat |
| K A Gronau, P L Brubake. Mechanism of action of glucagon-like peptide-1(7-36NH2) in isolated rat pancreatic islets and abrogation of its effects in long-term incubations. Endocrine. vol 3. issue 11. 2012-10-02. PMID:21153123. |
the results of the present study establish for the first time that glp-1(7-36nh2) induces insulin secretion in normal b cells through a protein kinase a-dependent mechanism. |
2012-10-02 |
2023-08-12 |
rat |
| K A Gronau, P L Brubake. Mechanism of action of glucagon-like peptide-1(7-36NH2) in isolated rat pancreatic islets and abrogation of its effects in long-term incubations. Endocrine. vol 3. issue 11. 2012-10-02. PMID:21153123. |
the loss of insulinotropic effect of glp-1(7-36nh2) in long-term incubations, despite the ability of glucose and camp to increase insulin secretion, suggests that the glp-1(7-37/36nh2) receptor in normal islets may undergo homologous desensitization during chronic exposure to glp-1(7-36nh2). |
2012-10-02 |
2023-08-12 |
rat |
| B Ahré. Antidiabetogenic action of truncated glucagon-like peptide-1 in mice. Endocrine. vol 3. issue 5. 2012-10-02. PMID:21153189. |
besides its well-known stimulatory action on insulin secretion, glucagon-like peptide-1 (7-36)amide (= glp-1) has been shown to increase the insulin-independent glucose uptake in normal individuals and the glucose elimination rate during short term conditions in diabetes. |
2012-10-02 |
2023-08-12 |
mouse |
| B Ahré. Antidiabetogenic action of truncated glucagon-like peptide-1 in mice. Endocrine. vol 3. issue 5. 2012-10-02. PMID:21153189. |
in normal animals, glp-1 also potentiated glucose-stimulated insulin secretion. |
2012-10-02 |
2023-08-12 |
mouse |
| M L Villanueva-Peñacarrillo, E Delgado, D Vicent, E Mérida, A I Alcántara, I Valverd. GLP-1(7-36)amide binding in skeletal muscle membranes from streptozotocin diabetic rats. Endocrine. vol 3. issue 9. 2012-10-02. PMID:21153227. |
as glp-1(7-36)amide exerts a glycogenic effect in the rat skeletal muscle, the present data suggest that the action of the peptide in the muscle glucose metabolism may be increased in states of insulin deficiency accompanied or not by insulin resistance. |
2012-10-02 |
2023-08-12 |
rat |
| Ronald Christopher, Aziz Kari. Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes. Expert review of clinical pharmacology. vol 2. issue 6. 2012-10-02. PMID:22112254. |
glp-1 and gip are released in response to food ingestion; they enhance nutrient-induced insulin secretion and inhibit postprandial glucagon secretion. |
2012-10-02 |
2023-08-12 |
human |
| Chrysi Koliaki, John Doupi. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 2. issue 2. 2012-10-02. PMID:22127804. |
the pancreatic effects of glp-1 receptor agonists include glucose-lowering effects by stimulating insulin secretion and inhibiting glucagon release in a strictly glucose-dependent manner, increased beta-cell proliferation, and decreased beta-cell apoptosis. |
2012-10-02 |
2023-08-12 |
human |
| Yu-Ting A Chiang, Wilfred Ip, Tianru Ji. The role of the Wnt signaling pathway in incretin hormone production and function. Frontiers in physiology. vol 3. 2012-10-02. PMID:22934027. |
in addition to insulin and glucagon produced by pancreatic islets, two incretin hormones, namely glucagon-like peptide-1 (glp-1) and gastric inhibitory polypeptide (gip, also known as glucose-dependent insulinotropic peptide), also play important roles in blood glucose homeostasis. |
2012-10-02 |
2023-08-12 |
Not clear |
| Jinmi Lee, Seok-Woo Hong, Eun-Jung Rhee, Won-Young Le. GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease. Diabetes & metabolism journal. vol 36. issue 4. 2012-10-02. PMID:22950055. |
glucagon-like peptide-1 (glp-1) is an incretin that increases insulin sensitivity and aids glucose metabolism. |
2012-10-02 |
2023-08-12 |
Not clear |
| Edoardo Mannucci, Ilaria Dicembrin. Incretin-based therapies and cardiovascular risk. Current medical research and opinion. vol 28. issue 5. 2012-09-28. PMID:22439700. |
glucagon-like peptide-1 (glp-1) receptor agonists and dipeptidyl peptidase 4 (dpp4) inhibitors are currently used as glucose-lowering agents in type 2 diabetes, due to their effects on insulin and glucagon secretion. |
2012-09-28 |
2023-08-12 |
Not clear |
| Xiaobing Du, Jennifer R Kosinski, Julie Lao, Xiaolan Shen, Aleksandr Petrov, Gary G Chicchi, George J Eiermann, Alessandro Poca. Differential effects of oxyntomodulin and GLP-1 on glucose metabolism. American journal of physiology. Endocrinology and metabolism. vol 303. issue 2. 2012-09-28. PMID:22621866. |
glucagon-like peptide-1 (glp-1) and oxyntomodulin (oxm) are peptide hormones secreted postprandially from the gut that stimulate insulin secretion in a glucose-dependent manner. |
2012-09-28 |
2023-08-12 |
mouse |
| Roberto Burattini, Micaela Morettin. Identification of an integrated mathematical model of standard oral glucose tolerance test for characterization of insulin potentiation in health. Computer methods and programs in biomedicine. vol 107. issue 2. 2012-09-27. PMID:21803437. |
model behaviour was tested vs. mean plasma glucagon-like peptide 1 (glp-1), glucose-dependent insulinotropic polypeptide (gip), glucose and insulin measurements from two different laboratories, where glycemic profiles observed during a 75 g ogtt were matched in healthy subjects (hc1- and hc2-group, respectively) by means of an isoglycemic intravenous glucose (i-ivg) infusion. |
2012-09-27 |
2023-08-12 |
human |
| Roberto Burattini, Micaela Morettin. Identification of an integrated mathematical model of standard oral glucose tolerance test for characterization of insulin potentiation in health. Computer methods and programs in biomedicine. vol 107. issue 2. 2012-09-27. PMID:21803437. |
under the hypothesis of an additive effect of glp-1 and gip on insulin potentiation, our results demonstrated a substantial equivalence of the two models in matching the data. |
2012-09-27 |
2023-08-12 |
human |
| S Mudaliar, R R Henr. The incretin hormones: from scientific discovery to practical therapeutics. Diabetologia. vol 55. issue 7. 2012-09-25. PMID:22555471. |
in 1986 they first documented a reduced incretin effect in patients with type 2 diabetes (diabetologia 29:46-52), and then in 1993 they demonstrated that, in patients with poorly controlled type 2 diabetes, a single exogenous infusion of an incretin (glp-1) increased insulin levels in a glucose-dependent manner and normalised fasting hyperglycaemia (diabetologia 36:741-744). |
2012-09-25 |
2023-08-12 |
Not clear |
| Colin A Leech, Igor Dzhura, Oleg G Chepurny, Guoxin Kang, Frank Schwede, Hans-G Genieser, George G Hol. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells. Progress in biophysics and molecular biology. vol 107. issue 2. 2012-09-20. PMID:21782840. |
insulin secretion from pancreatic β cells is stimulated by glucagon-like peptide-1 (glp-1), a blood glucose-lowering hormone that is released from enteroendocrine l cells of the distal intestine after the ingestion of a meal. |
2012-09-20 |
2023-08-12 |
Not clear |
| Colin A Leech, Igor Dzhura, Oleg G Chepurny, Guoxin Kang, Frank Schwede, Hans-G Genieser, George G Hol. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells. Progress in biophysics and molecular biology. vol 107. issue 2. 2012-09-20. PMID:21782840. |
glp-1 mimetics (e.g., byetta) and glp-1 analogs (e.g., victoza) activate the β cell glp-1 receptor (glp-1r), and these compounds stimulate insulin secretion while also lowering levels of blood glucose in patients diagnosed with type 2 diabetes mellitus (t2dm). |
2012-09-20 |
2023-08-12 |
Not clear |
| Colin A Leech, Igor Dzhura, Oleg G Chepurny, Guoxin Kang, Frank Schwede, Hans-G Genieser, George G Hol. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells. Progress in biophysics and molecular biology. vol 107. issue 2. 2012-09-20. PMID:21782840. |
investigational compounds that stimulate glp-1 secretion also exist, and in this regard a noteworthy advance is the demonstration that small molecule gpr119 agonists (e.g., ar231453) stimulate l cell glp-1 secretion while also directly stimulating β cell insulin release. |
2012-09-20 |
2023-08-12 |
Not clear |